Targeted & controlled bone healing
23 Jun 16
First Trading Day of New Kuros Share after Reverse Split

Schlieren (Zurich), Switzerland, June 23, 2016

First Trading Day of New Kuros Share after Reverse Split

Kuros Biosciences Ltd (“Kuros”) today announced the first trading day of the new shares after a reverse split at the ratio of 100 to 1 approved by the recent Annual Shareholders’ Meeting.

“The reverse split is expected to simplify the trading and increase the shares’ attractiveness for investors”, explained Harry Welten, Chief Financial Officer.

 

Shareholders approved the reverse stock split at the Annual Shareholders’ Meeting on June 16, 2016. 100 existing registered shares with a nominal value of CHF 0.01 each were exchanged into 1 new (merged) registered share with a nominal value of CHF 1.00. To allow the allocation of a rounded number of shares, current shareholders and founders Dr. Jeffrey Hubbell and Didier Cowling provided the other shareholders for no consideration with the number of shares required. As a result, each existing shareholder received at least one new (merged) share and in any event, a rounded number of shares.



Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Article
23 Jun 16
First Trading Day of New Kuros Share after Reverse Split

Schlieren (Zurich), Switzerland, June 23, 2016

First Trading Day of New Kuros Share after Reverse Split

Kuros Biosciences Ltd (“Kuros”) today announced the first trading day of the new shares after a reverse split at the ratio of 100 to 1 approved by the recent Annual Shareholders’ Meeting.

“The reverse split is expected to simplify the trading and increase the shares’ attractiveness for investors”, explained Harry Welten, Chief Financial Officer.

 

Shareholders approved the reverse stock split at the Annual Shareholders’ Meeting on June 16, 2016. 100 existing registered shares with a nominal value of CHF 0.01 each were exchanged into 1 new (merged) registered share with a nominal value of CHF 1.00. To allow the allocation of a rounded number of shares, current shareholders and founders Dr. Jeffrey Hubbell and Didier Cowling provided the other shareholders for no consideration with the number of shares required. As a result, each existing shareholder received at least one new (merged) share and in any event, a rounded number of shares.